Design and evaluation of novel liposome-based peptide vaccines for improved efficacy against group A streptococcal infections of the mucosa and skin
Author(s)
Primary Supervisor
Good, Michael
Pandey, Manisha
Other Supervisors
Batzloff, Michael
Year published
2018
Metadata
Show full item recordAbstract
Streptococcus pyogenes (group A streptococcus, GAS) is an important human pathogen that is responsible for a range of diseases. Non-invasive diseases include pharyngitis, scarlet fever and pyoderma/impetigo. GAS is also capable of causing invasive diseases such as streptococcal toxic shock syndrome and necrotizing fasciitis. There is a high chance of mortality associated with GAS invasive diseases, with approximately 8-23% of patients dying within 7 days of infection. Consecutive GAS infections may give rise to auto-immune complications, including acute rheumatic fever (ARF) and rheumatic heart disease (RHD). Approximately ...
View more >Streptococcus pyogenes (group A streptococcus, GAS) is an important human pathogen that is responsible for a range of diseases. Non-invasive diseases include pharyngitis, scarlet fever and pyoderma/impetigo. GAS is also capable of causing invasive diseases such as streptococcal toxic shock syndrome and necrotizing fasciitis. There is a high chance of mortality associated with GAS invasive diseases, with approximately 8-23% of patients dying within 7 days of infection. Consecutive GAS infections may give rise to auto-immune complications, including acute rheumatic fever (ARF) and rheumatic heart disease (RHD). Approximately 2-3% of patients who acquire streptococcal pharyngitis develop ARF. Skin-associated GAS strains have also been linked to cases of ARF. A vaccine that can stop the progression of disease from the primary sites of infection (URT and skin) is desperately needed.
View less >
View more >Streptococcus pyogenes (group A streptococcus, GAS) is an important human pathogen that is responsible for a range of diseases. Non-invasive diseases include pharyngitis, scarlet fever and pyoderma/impetigo. GAS is also capable of causing invasive diseases such as streptococcal toxic shock syndrome and necrotizing fasciitis. There is a high chance of mortality associated with GAS invasive diseases, with approximately 8-23% of patients dying within 7 days of infection. Consecutive GAS infections may give rise to auto-immune complications, including acute rheumatic fever (ARF) and rheumatic heart disease (RHD). Approximately 2-3% of patients who acquire streptococcal pharyngitis develop ARF. Skin-associated GAS strains have also been linked to cases of ARF. A vaccine that can stop the progression of disease from the primary sites of infection (URT and skin) is desperately needed.
View less >
Thesis Type
Thesis (PhD Doctorate)
Degree Program
Doctor of Philosophy (PhD)
School
Institute for Glycomics
Copyright Statement
The author owns the copyright in this thesis, unless stated otherwise.
Subject
Medical and Health Sciences
Peptide vaccines
Streptococcal infections
Liposomal-based delivery systems
Mucosal vaccine platform
Skin-infection